Johnson & Johnson subsidiary Janssen Pharmaceutical has received approval to launch a phase 1 COVID-19 vaccine trial in Brazil.

Janssen’s Ad26.COV2.S becomes the fourth vaccine hopeful to begin a trial in Brazil, which is second only to the U.S. in COVID-19 outbreak statistics. The country has recorded 3.4 million COVID-19 cases and more than 108,000 related deaths.

Janssen aims to recruit 6,000 participants for the Brazilian trial.